Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13304
Peer-review started: October 19, 2022
First decision: November 4, 2022
Revised: November 19, 2022
Accepted: November 28, 2022
Article in press: November 28, 2022
Published online: December 26, 2022
Processing time: 68 Days and 8.3 Hours
Cervical cancer is a gynecological malignancy that is common in middle-aged and older patients, with a high mortality rate; it seriously endangers the health of patients. Spondin-2 is an important molecular marker that is involved in innate and acquired immune responses. This study focused on the relationship between serum Spondin-2 expression, tumor invasion and infiltration, and immune response in patients with cervical cancer to provide a theoretical basis for clinical practice.
The motivation of this study was to investigate the differences in serum Spondin-2 expression levels in patients with cervical cancer, patients with benign uterine lesions, and healthy subjects, as well as the relationship between serum Spondin-2 Levels, tumor invasion and infiltration, and antitumor immune response.
This study aimed to investigate the relationship between serum Spondin-2 expression, tumor invasion and infiltration, and antitumor immune response in patients with cervical cancer.
We detected Spondin-2 expression in the sera of patients with cervical cancer or benign uterine lesions and in those of healthy subjects. According to the threshold of Spondin-2 used in cervical cancer diagnosis, patients with cervical cancer were divided into high Spondin-2 and low Spondin-2 groups. Clinicopathological features, immune cytokine levels, and prognosis of patients with different levels of Spondin-2 expression were compared.
The serum Spondin-2 expression level was significantly higher in the cervical cancer group than in the benign and control groups. The proportion of patients with Federation of Gynecology and Obstetrics stage III, nerve invasion, vascular invasion, and lymph node metastasis was higher in the high Spondin-2 group than in the low Spondin-2 group. The levels of interleukin (IL)-5 and IL-4 were higher in the high Spondin-2 group than in the low Spondin-2 group, whereas the levels of IL-2 and tumor necrosis factor-α were lower in the high Spondin-2 group than in the low Spondin-2 group. After 3 years of follow-up, progression-free survival and overall survival were significantly lower in the high Spondin-2 group than in the low Spondin-2 group.
The expression of Spondin-2 in patients with cervical cancer was upregulated, and it was associated with tumor invasion and infiltration, antitumor immune response, and prognosis.
Serum Spondin-2 Levels can be used as a new diagnostic marker and therapeutic target for cervical cancer, providing a theoretical basis for clinical diagnosis and disease evaluation.